# Regen BioPharma, Inc. (RGBP)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/RGBP/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 31.6K | $ 991.9K | $ -63.2K | $ 968.1K | $ -5.36M |
| 2025 | $ 242.2K | $ -1.77M | $ -527.5K | $ 1.21M | $ -6.57M |
| 2024 | $ 248.6K | $ -1.07M | $ -627.7K | $ 873.1K | $ -5.60M |
| 2023 | $ 255.4K | $ -848.2K | $ -352.3K | $ 714.1K | $ -5.24M |
| 2022 | $ 263.1K | $ -5.09M | $ -377.9K | $ 511.6K | $ -4.88M |
| 2021 | $ -1.99M | $ -9.08M | $ -1.68M | $ 2.72M | $ -9.76M |
| 2020 | $ 140.1K | $ 1.06M | $ 816.1K | $ 2.59M | $ -5.58M |
| 2019 | $ 142.0K | $ -593.2K | $ -396.9K | $ 2.21M | $ -7.70M |
| 2018 | $ 300.4K | $ -2.74M | $ -1.45M | $ 1.64M | $ -8.66M |
| 2017 | $ 296.4K | $ -10.84M | $ -2.72M | $ 936.3K | $ -7.80M |
| 2016 | $ 137.6K | $ -6.51M | $ -467.9K | $ 245.8K | $ -156.1K |
| 2015 | $ 269.6K | $ -3.88M | $ -17.76M | $ 168.1K | $ -22.0K |
| 2014 | $ -8.2K | $ -1.08M | $ -3.16M | $ 305.9K | $ -261.4K |
| 2013 | $ 0 | $ -673.0K | $ -549.1K | $ 0 | $ 251.4K |
| 2012 | $ 0 | $ -132.6K | $ -132.6K | $ 0 | $ 923 |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | -0.18 |
| Liabilities / Eq | -1.05 |
| Current Ratio | 0.05 |

## Other views

- [Metrics](https://sponda.capital/en/RGBP.md)
- [Charts](https://sponda.capital/en/RGBP/charts.md)
- [Compare](https://sponda.capital/en/RGBP/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-13.